[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
July 7, 1999

Trovafloxacin Public Health Advisory

Author Affiliations

Not Available

Not Available

JAMA. 1999;282(1):19. doi:10.1001/jama.282.1.19-JFD90005-2-1

The FDA has issued a public health advisory to inform physicians and the public regarding new safety information about trovafloxacin/alatrofloxacin (Trovan, Trovan-IV), a quinolone antibiotic marketed since February 1998 for a broad range of infections. Based on new safety data related to serious liver injury, the manufacturer has agreed to limit distribution of the product to hospitals and long-term nursing care facilities, and the FDA is advising physicians that the drug should be reserved for treatment only in patients who meet all of the following criteria:

First Page Preview View Large
First page PDF preview
First page PDF preview